万泰生物举办资本市场专项调研会

Core Viewpoint - The company is focusing on its strengths in the vaccine and in vitro diagnostic fields, emphasizing its international strategic layout and future growth potential during a recent capital market research conference [2][3]. Group 1: Company Overview - The research conference attracted over 20 securities analysts from firms such as CITIC Securities and Guolian Minsheng Securities, highlighting significant interest in the company's developments [3]. - The general manager of the company, Jiang Zhiming, reviewed the company's 30-year development history and outlined its strategic layout, focusing on product advantages, innovative models, and international expansion [3]. Group 2: Market Opportunities - The HPV vaccine market in China shows significant potential, with a first-dose coverage rate of 27.43% among women aged 9-45, compared to 67% in Western countries, indicating a theoretical market of over 100 million people [4]. - The company plans to implement differentiated sales strategies based on regional demographics, consumer capabilities, and healthcare resource distribution to tap into this market [4]. Group 3: Innovation and Development - The company has established a comprehensive technical platform covering vaccines and in vitro diagnostics, focusing on products with broad market prospects and committing to increased innovation investment [5]. - The recent research conference served as an important opportunity for the company to enhance communication with the capital market, showcasing its core competitiveness and global strategy in the vaccine and in vitro diagnostic sectors [5].